1. Home
  2. MBAI vs IMRN Comparison

MBAI vs IMRN Comparison

Compare MBAI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

HOLD

Current Price

$7.97

Market Cap

8.8M

Sector

N/A

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.08

Market Cap

9.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBAI
IMRN
Founded
2004
1994
Country
Israel
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8M
9.6M
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
MBAI
IMRN
Price
$7.97
$1.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
76.7K
20.0K
Earning Date
05-12-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.95
$0.68
52 Week High
$10.21
$2.38

Technical Indicators

Market Signals
Indicator
MBAI
IMRN
Relative Strength Index (RSI) 89.50 50.58
Support Level $1.19 $0.98
Resistance Level N/A $1.22
Average True Range (ATR) 0.38 0.07
MACD 0.87 0.00
Stochastic Oscillator 79.81 71.43

Price Performance

Historical Comparison
MBAI
IMRN

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: